Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab Dose Comparison for Threshold Retinopathy of Prematurity
ChiCTR2100043345Phase 4Completed
- Sponsor
- Guangzhou Women and Children's Medical Center
- Start
- Oct 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4 trial of bevacizumab in retinopathy of prematurity (ROP) (3 arms), sponsored by Guangzhou Women and Children's Medical Center. Primary endpoint: Changes in ocular fundus. Started Oct 2016; status: completed.
02
Drugs
bevacizumab
03
Conditions
retinopathy of prematurity (ROP)
Beyond the preview
Go deeper on ChiCTR2100043345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100043345.